UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 52

Sortiert nach

KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS

Depression and anxiety, 2016-08, Vol.33 (8), p.689-697

2016

Volltextzugriff (PDF)

Synaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic

Current psychiatry reports, 2017-10, Vol.19 (10), p.74-74, Article 74

2017

Volltextzugriff (PDF)

Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Antidepressant Efficacy of Ketamine in Depressed Patients

Biological psychiatry (1969), 2012-12, Vol.72 (11), p.e27-e28

2012

Volltextzugriff (PDF)

The Role of Stress in the Pathogenesis and Maintenance of Obsessive-Compulsive Disorder

Chronic Stress, 2018, Vol.2, p.247054701875804

2018

Volltextzugriff (PDF)

Transcranial direct current stimulation targeting the medial prefrontal cortex modulates functional connectivity and enhances safety learning in obsessive‐compulsive disorder: Results from two pilot studies

Depression and anxiety, 2022-01, Vol.39 (1), p.37-48

2022

Volltextzugriff (PDF)

Stress Response Modulation Underlying the Psychobiology of Resilience

Current psychiatry reports, 2018-04, Vol.20 (4), p.27-27, Article 27

2018

Volltextzugriff (PDF)

Methylone is a rapid-acting neuroplastogen with less off-target activity than MDMA

Frontiers in neuroscience, 2024, Vol.18, p.1353131-1353131

2024

Volltextzugriff (PDF)

Methylone, a rapid acting entactogen with robust anxiolytic and antidepressant-like activity

Frontiers in psychiatry, 2023-01, Vol.13, p.1041277-1041277

2023

Volltextzugriff (PDF)

PTSD: from neurobiology to pharmacological treatments

European journal of psychotraumatology, 2016-01, Vol.7 (1), p.31858-11

2016

Volltextzugriff (PDF)

Pilot study suggests DNA methylation of the glucocorticoid receptor gene (NR3C1) is associated with MDMA-assisted therapy treatment response for severe PTSD

Frontiers in psychiatry, 2023-02, Vol.14, p.959590-959590

2023

Volltextzugriff (PDF)

Pharmacological effects of methylone and MDMA in humans

Frontiers in pharmacology, 2023-02, Vol.14, p.1122861-1122861

2023

Volltextzugriff (PDF)

Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive-compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial

Frontiers in psychiatry, 2023-04, Vol.14, p.1178529-1178529

2023

Volltextzugriff (PDF)

Prefrontal Glutamate Neurotransmission in PTSD: A Novel Approach to Estimate Synaptic Strength in Vivo in Humans

Chronic stress (Thousand Oaks, Calif.), 2022-01, Vol.6, p.24705470221092734-24705470221092734

2022

Volltextzugriff (PDF)

Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report

Heliyon, 2022-12, Vol.8 (12), p.e12135, Article e12135

2022

Volltextzugriff (PDF)

Overview of glutamatergic neurotransmission in the nervous system

Pharmacology, biochemistry and behavior, 2012-02, Vol.100 (4), p.656-664

2012

Volltextzugriff (PDF)

Psychedelics

Current biology, 2022-01, Vol.32 (2), p.R63-R67

2022

Volltextzugriff (PDF)

Imagery Rescripting (ImRs) as an Adjunctive Treatment to Exposure and Response Prevention (ERP)-Resistant Obsessive-Compulsive Disorder: A Case Study

Clinical case studies, 2023-04, Vol.22 (2), p.174-191

2023

Volltextzugriff (PDF)

W161 - Differing Approaches to Investigating the Therapeutic Efficacy of Psilocybin Across Diverse Indications

Drug and alcohol dependence, 2024-07, Vol.260

2024

Volltextzugriff (PDF)

Differing Approaches to Investigating the Therapeutic Efficacy of Psilocybin Across Diverse Indications

Drug and alcohol dependence, 2024-07, Vol.260, p.110862, Article 110862

2024

Volltextzugriff (PDF)

Mechanisms of therapeutic change after psychedelic treatment in OCD

Psychiatry research, 2024-06, Vol.336, p.115907, Article 115907

2024

Volltextzugriff (PDF)

Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2023-09, Vol.330 (9), p.843

2023

Volltextzugriff (PDF)

Enhancing Trauma-Memories Reconsolidation With One-Time Ketamine Infusion

Biological psychiatry (1969), 2021-05, Vol.89 (9), p.S298-S298

2021

Volltextzugriff (PDF)

O40. PTSD Augmented Psychotherapy With Ketamine (KPE) - First Results

Biological psychiatry (1969), 2019-05, Vol.85 (10), p.S122-S122

2019

Volltextzugriff (PDF)

1 – 25 von 52

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(46)

Publikationsform

Sprache

Englisch
(52)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS

Synaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic

Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Antidepressant Efficacy of Ketamine in Depressed Patients

The Role of Stress in the Pathogenesis and Maintenance of Obsessive-Compulsive Disorder

Transcranial direct current stimulation targeting the medial prefrontal cortex modulates functional connectivity and enhances safety learning in obsessive‐compulsive disorder: Results from two pilot studies

Stress Response Modulation Underlying the Psychobiology of Resilience

Methylone is a rapid-acting neuroplastogen with less off-target activity than MDMA

Methylone, a rapid acting entactogen with robust anxiolytic and antidepressant-like activity

PTSD: from neurobiology to pharmacological treatments

Pilot study suggests DNA methylation of the glucocorticoid receptor gene (NR3C1) is associated with MDMA-assisted therapy treatment response for severe PTSD

Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings

Pharmacological effects of methylone and MDMA in humans

Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive-compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial

Corrigendum: Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings

Prefrontal Glutamate Neurotransmission in PTSD: A Novel Approach to Estimate Synaptic Strength in Vivo in Humans

Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report

Overview of glutamatergic neurotransmission in the nervous system

Psychedelics

Imagery Rescripting (ImRs) as an Adjunctive Treatment to Exposure and Response Prevention (ERP)-Resistant Obsessive-Compulsive Disorder: A Case Study

W161 - Differing Approaches to Investigating the Therapeutic Efficacy of Psilocybin Across Diverse Indications

Differing Approaches to Investigating the Therapeutic Efficacy of Psilocybin Across Diverse Indications

Mechanisms of therapeutic change after psychedelic treatment in OCD

Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial

Enhancing Trauma-Memories Reconsolidation With One-Time Ketamine Infusion

O40. PTSD Augmented Psychotherapy With Ketamine (KPE) - First Results

Suchergebnisse filtern